The global pharmaceutical contract development and manufacturing organization Alcami has appointed Patrick D. Walsh as Chairman and Chief Executive Officer, effective immediately. He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.

"Patrick brings a depth of industry knowledge and leadership experience that will support Alcami's strategic efforts to continue to add scale in attractive growth markets and deliver high-quality services to the pharmaceutical industry," commented Jason Shideler, a Managing Director on Madison Dearborn Partners' Health Care team and Lead Director at Alcami.

Prior to joining Alcami, Walsh was Co-Founder and CEO of TriPharm Services, a parenteral manufacturing business that was acquired by Alcami in January 2020. From 2015 to 2019, Walsh was the Chief Executive Officer of Avista Pharma, a private equity-backed global provider of contract manufacturing, development, and analytical testing services. Walsh also served as CEO of AAIPharma Services Corporation, a predecessor company to Alcami, from 2010 to 2014.

In addition to his duties at Alcami, Walsh currently serves as Chairman of ANI Pharmaceuticals, a director at Landec Corporation, and a director at Industria Chemica Emiliano (I.C.E).